binding affinity News and Research

RSS

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.

13 May 2021

SARS-CoV-2 UK variant more infectious because of higher viral load

The coronavirus disease 2019 (COVID-19) pandemic was triggered by the uncontrolled spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A year and a half later, the relationship between SARS-CoV-2 viral load and infectiousness remains a matter of scientific debate. Now, a new preprint research paper posted to the bioRxiv server aims to quantify this relationship

11 May 2021

Novel pipeline identifies millions of molecular targets in SARS-CoV-2

Researchers in the United States have developed a novel pipeline for high-throughput, automated annotation of the genes, proteins and functional domains in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.

29 Apr 2021

SARS-CoV-2 recruits heme metabolites in antibody evasion

A research paper recently published in the journal Science Advances by Cherepanov et al. (April 22nd, 2021) demonstrated that the NTD binds to biliverdin, a product of heme catabolism, leading to enhanced antibody escape at physiologically relevant concentrations.

28 Apr 2021

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

A new study in the journal JAMA Network reports on the disease severity associated with some clades of the virus, from an analysis of genomes from specimens isolated in the initial phase of the pandemic.

27 Apr 2021

Study identifies mechanism behind SARS-CoV-2 viral protein production

A new study from German researchers examines how SARS viruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hijack cells and reprogram them to enhance viral replication.

27 Apr 2021

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

The SARS-CoV-2 B.1.1.7 variant, also called the UK variant, was identified in London as well as in Southeast and East of England in December 2020. Since its emergence, the UK variant has undergone several mutations that have been said to have altered its infectivity and transmissibility in the community. The B.1.1.7 variant is defined by 17 mutations, several of which are located in the SARS-CoV-2 spike protein that mediates viral attachment and entry into human cells.

21 Apr 2021

What do we know about the origin and evolution of SARS-CoV-2?

A new study examines the origin and continuing evolution of SARS-CoV-2 in the human and animal co-hosts in an attempt to help prepare for future destructive outbreaks.

21 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

A new study led by Hans-Martin Jäck of the Friedrich-Alexander University Erlangen-Nuremberg in Germany engineered clusters of neutralizing monoclonal antibodies using a transgenic mouse model. A unique characteristic for the antibodies was the different ways it bound to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the overall reduction in the viral spread for human ACE2.

21 Apr 2021

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

A team of international scientists recently demonstrated that antibodies generated in response to the DNA vaccine INO-4800 can effectively neutralize some of the recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as G614, 501Y.V1, and 501Y.V2.

20 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Could a tuna-derived protein inhibit SARS-CoV-2?

A recent study in the journal Food Chemistry draws attention to the need for finding nutritional supplements with potential SARS-CoV-2 inhibition effects in the wake of the COVID-19 pandemic.

19 Apr 2021

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

Researchers in the United States have predicted the binding epitopes of uncharacterized neutralizing antibodies that target the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

ACE2 homology in laboratory and wild animals

A new preprint research paper posted to the bioRxiv server describes the conservation of an important receptor gene for the virus among several animal species that live in close contact or proximity to humans.

13 Apr 2021

binding affinity News and Research

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

SARS-CoV-2 UK variant more infectious because of higher viral load

Novel pipeline identifies millions of molecular targets in SARS-CoV-2

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

SARS-CoV-2 recruits heme metabolites in antibody evasion

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

Study identifies mechanism behind SARS-CoV-2 viral protein production

B.1.1.7 variant 45% more infectious than wild-type SARS-CoV-2, but can be effectively contained by BNT162b2 vaccine

What do we know about the origin and evolution of SARS-CoV-2?

Immune escape by SARS-CoV-2 mutations acquired in mink

Characterization of lab-produced neutralizing antibodies targeting SARS-CoV-2

Humoral immunity developed by DNA vaccine INO-4800 is effective against SARS-CoV-2 variants

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Could a tuna-derived protein inhibit SARS-CoV-2?

Study sheds light on reduced neutralization of SARS-CoV-2 variants of concern

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

ACE2 homology in laboratory and wild animals

Binding kinetics in drug discovery eBook eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News